

DOL Wage and Hour Division (WHD) the Office of Management and Budget (OMB) Information Control No. 1235–0008, Davis-Bacon Certified Payroll or 1235–0018, Records to be kept by Employers—Fair Labor Standards Act.

*Respondents:* 182 (170 prime contractors plus 12 subcontractors).

*Responses per Respondent:* 52 (1 for each week of the year).

*Total Annual Responses:* 9,464 (182 respondents × 52 responses).

*Hours per Response:* 33 minutes (weighted average of 56 minutes (DOL estimated time to input information plus 1 minute recordkeeping for initial entry) + 31 minutes (estimated time to certify payroll in new system plus 1 minute recordkeeping)).

*Total Burden Hours:* 5,205 (9,464 annual responses × 33 minutes/60 minutes).

### C. Public Comments

A 60-day notice published in the **Federal Register** at 90 FR 33949 on July 18, 2025. No comments were received.

*Obtaining Copies of Proposals:* Requesters may obtain a copy of the information collection documents from the Regulatory Secretariat Division by calling 202–501–4755 or emailing [GSARegSec@gsa.gov](mailto:GSARegSec@gsa.gov). Please cite OMB Control No. 3090–0326, Construction Payrolls and Basic Records, in all correspondence.

**Jeffrey A. Koses,**

*Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.*

[FR Doc. 2025–19396 Filed 10–2–25; 8:45 am]

**BILLING CODE 6820–61–P**

## OFFICE OF GOVERNMENT ETHICS

### Updated OGE Senior Executive Service Performance Review Board

**AGENCY:** Office of Government Ethics (OGE).

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given of the appointment of members to the OGE Senior Executive Service (SES) Performance Review Board.

**DATES:** *Effective date:* October 3, 2025.

**FOR FURTHER INFORMATION CONTACT:**

Shelley K. Finlayson, Chief of Staff and Chief Counsel, U. S. Office of Government Ethics, 250 E Street SW, Suite 750, Washington, DC 20024; Telephone: 202–482–9314; TTY: 800–877–8339; FAX: 202–482–9237.

**SUPPLEMENTARY INFORMATION:** Federal law at 5 U.S.C. 4314(c) requires each agency to establish, in accordance with

regulations prescribed by the Office of Personnel Management at 5 CFR part 430, subpart C and § 430.310 thereof in particular, one or more SES performance review boards. As a small executive branch agency, OGE has just one board. To ensure an adequate level of staffing and to avoid a constant series of recusals, the designated members of OGE's SES Performance Review Board are being drawn, as in the past, in large measure from the ranks of other executive branch agencies. The board shall review and evaluate the initial appraisal of each OGE senior executive's performance by his or her supervisor, along with any recommendations in each instance to the appointing authority relative to the performance of the senior executive. This notice updates the membership of OGE's SES Performance Review Board as it was most recently published at 89 FR 81530 (October 8, 2024).

The following officials have been appointed to the SES Performance Review Board of OGE: Katherine Easmunt, Chief Ethics Counsel, National Credit Union Administration; Stuart Bender, Director, USDA Office of Ethics, U.S. Department of Agriculture; and Natalie A. Bonanno, Associate General Counsel and Chief Ethics Compliance Officer, U.S. Postal Service.

*Authority:* 5 U.S.C. 4314(c)(4).

Approved: September 30, 2025.

**Shelley K. Finlayson,**

*Chief of Staff and Chief Counsel, Office of Government Ethics.*

[FR Doc. 2025–19442 Filed 10–2–25; 8:45 am]

**BILLING CODE 6345–04–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2025–N–2422]

#### Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** on August 4, 2025 (90 FR 36440). The document announced the withdrawal of approval of 39 new drug applications (NDA) from multiple applicants, withdrawn as of September 3, 2025. The document erroneously included NDA number 021290. The

correct NDA number is 020212 for Zinecard (dexrazoxane hydrochloric acid (HCl)) Injectable, equivalent to (EQ) 250 milligrams (mg) base/vial and EQ 500 mg base/vial. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993–0002, 301–796–3137, [Kimberly.Lehrfeld@fda.hhs.gov](mailto:Kimberly.Lehrfeld@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** issue published August 4, 2025 (90 FR 36440), the NDA number for Zinecard (dexrazoxane HCl) Injectable, EQ 250 mg base/vial and EQ 500 mg base/vial is corrected to 020212.

**Grace R. Graham,**

*Deputy Commissioner for Policy, Legislation, and International Affairs.*

[FR Doc. 2025–19440 Filed 10–2–25; 8:45 am]

**BILLING CODE 4164–01–P**

## INTERNATIONAL TRADE COMMISSION

[Investigation No. 731–TA–1125 (Third Review)]

### Electrolytic Manganese Dioxide From China; Scheduling of an Expedited Five-Year Review

**AGENCY:** United States International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** The Commission hereby gives notice of the scheduling of an expedited review pursuant to the Tariff Act of 1930 (“the Act”) to determine whether revocation of the antidumping duty order on electrolytic manganese dioxide from China would be likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time.

**DATES:** September 5, 2025.

**FOR FURTHER INFORMATION CONTACT:**

Laurel Schwartz (202–205–2398), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (<https://>